Clinical Evidence for Use of a Noninvasive Biosensor for Tear Glucose as an Alternative to Painful Finger-Prick for Diabetes Management Utilizing a Biopolymer Coating.
Alicja E KownackaDovile VegelyteMaurits JoosseNicoleta AntonB Jelle ToebesJan LaukoIrene BuzzaccheraKatarzyna LipinskaDaniela A WilsonNel Geelhoed-DuijvestijnChristopher J WilsonPublished in: Biomacromolecules (2018)
Diabetes is a metabolic condition that is exponentially increasing worldwide. Current monitoring methods for diabetes are invasive, painful, and expensive. Herein, we present the first multipatient clinical trial that demonstrates clearly that tear fluid may be a valuable marker for systemic glucose measurements. The NovioSense Glucose Sensor, worn under the lower eye lid (inferior conjunctival fornix), is reported to continuously measure glucose levels in the basal tear fluid with good correlation to blood glucose values, showing clear clinical feasibility in both animals and humans. Furthermore, the polysaccharide coated device previously reported by our laboratory when worn, does not induce pain or irritation. In a phase II clinical trial, six patients with type 1 Diabetes Mellitus were enrolled and the capability of the device to measure glucose in the tear fluid was evaluated. The NovioSense Glucose Sensor gives a stable signal and the results correlate well to blood glucose values obtained from finger-prick measurements determined by consensus error grid analysis.
Keyphrases
- blood glucose
- glycemic control
- clinical trial
- phase ii
- type diabetes
- blood pressure
- cardiovascular disease
- open label
- insulin resistance
- ejection fraction
- study protocol
- weight loss
- end stage renal disease
- newly diagnosed
- neuropathic pain
- phase iii
- randomized controlled trial
- chronic pain
- adipose tissue
- spinal cord injury
- pain management
- spinal cord
- quantum dots
- peritoneal dialysis
- label free